Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Johnson & Johnson : Jury orders J&J to pay $4.7 billion in Missouri asbestos cancer case

share with twitter share with LinkedIn share with facebook
share via e-mail
07/13/2018 | 02:11am CEST
Logo of healthcare company Johnson & Johnson is seen in Zug

(Reuters) - A Missouri jury on Thursday ordered Johnson & Johnson to pay a record $4.69 billion (3.55 billion pounds) to 22 women who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer.

The verdict is the largest J&J has faced to date over allegations that its talc-based products cause cancer.

The company is battling some 9,000 talc cases. J&J denies both that its talc products cause cancer and that they ever contained asbestos. It says decades of studies show its talc to be safe and has successfully overturned previous talc verdicts on technical legal grounds.

Thursday's massive verdict, handed down in the Circuit Court of the City of St. Louis, was comprised of $550 million in compensatory damages and $4.14 billion in punitive damages, according to an online broadcast of the trial by Courtroom View Network.

J&J in a statement called the trial "fundamentally unfair" and said it would appeal the decision.

J&J shares fell $1.31, or 1 percent, to $126.45 in after-hours trading following the punitive damages award. They had risen $1.52 during regular trading.

The jury's decision followed more than five weeks of testimony by nearly a dozen experts on both sides.

The women and their families said decades-long use of Baby Powder and other cosmetic talc products caused their diseases. They allege the company knew its talc was contaminated with asbestos since at least the 1970s but failed to warn consumers about the risks.

"Johnson & Johnson is deeply disappointed in the verdict, which was the product of a fundamentally unfair process," the company said in a statement. The company said it remained confident that its products do not contain asbestos or cause cancer.

"Every verdict against Johnson & Johnson in this court that has gone through the appeals process has been reversed and the multiple errors present in this trial were worse than those in the prior trials which have been reversed," J&J added, saying that it would pursue all available appellate remedies.

J&J has successfully overturned talc verdicts in the past, with appeals courts pointing to a 2017 decision by the U.S. Supreme Court that limits where personal injury lawsuits can be filed.

Of the 22 women in the St. Louis trial, 17 were from outside Missouri, a state generally regarded as friendly towards plaintiffs. The practice of combining plaintiffs in such jurisdictions, commonly criticized as "forum shopping" by defendants, will be challenged on appeal.

Mark Lanier, the lawyer for the women, in a statement following the verdict called on J&J to pull its talc products from the market "before causing further anguish, harm, and death from a terrible disease."

"If J&J insists on continuing to sell talc, they should mark it with a serious warning," Lanier said.

The majority of the lawsuits that J&J faces involve claims that talc itself caused ovarian cancer, but a smaller number of cases allege that contaminated talc caused mesothelioma, a tissue cancer closely linked to asbestos exposure.

The cases that went to trial in St. Louis effectively combine those claims by alleging asbestos-contaminated talc caused ovarian cancer.

Previous talc trials have produced verdicts as large as $417 million. But that 2017 verdict by a California jury, as well as other verdicts in Missouri, was overturned on appeal, and challenges to at least another five verdicts are pending.

The U.S. Food and Drug Administration commissioned a study of various talc samples from 2009 to 2010, including of J&J's Baby Powder. No asbestos was found in any of the talc samples, the agency said https://bit.ly/2L5oXJP.

But Lanier during the trial told jurors that the agency and other laboratories and J&J have used flawed testing methods that did not allow for the proper detection of asbestos fibres.

Talc, the world's softest rock, is a mineral closely linked to asbestos and the two substances can appear in close proximity in the earth.

Plaintiffs claim the two can become intermingled in the mining process, making it impossible to remove the carcinogenic substance. J&J denies those allegations, saying rigorous testing and purification processes ensure its talc is clean.

(Reporting by Tina Bellon in New York; editing by Leslie Adler and Rosalba O'Brien)

By Tina Bellon

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
07/20JOHNSON & JOHNSON : Zach attack tames cold and wet Carnoustie
07/20JOHNSON & JOHNSO : johnson, & johnson
07/20JOHNSON & JOHNSON : Janssen Pharmaceutical - Phase 3 CREDENCE Renal Outcomes Tri..
07/20JOHNSON & JOHNSON : Announces Quarterly Dividend for Third Quarter 2018
07/20Eversight Expands Offer Innovation Suite to Address $760 Billion Consumer Pac..
07/20JOHNSON & JOHNSON : BioCentury - Provention raises $64M IPO
07/20JOHNSON & JOHNSON : and Reports 2018 Second-Quarter Results
07/20JOHNSON & JOHNSON : Bayer - Phil Sharp to join Bayer UK and Ireland
07/20GENMAB : Announces Net Sales of DARZALEX for Second Quarter of 2018
07/20JOHNSON & JOHNSON : Janssen Announces U.S. FDA Approval of SYMTUZATM, the First ..
More news
News from SeekingAlpha
07/20FDA releases updated industry guidelines for development of generic abuse-det.. 
07/20YOUR DAILY PHARMA SCOOP : Catalyst Bio Succeeds, CTI Moves Forward, Pfizer Posit.. 
07/20GERON : Anticipation Building 
07/19My Dividend Growth Portfolio - Q2 2018 Summary 
07/19Jane's June Dividend Increases And Income - Retirement Accounts 
Financials ($)
Sales 2018 81 273 M
EBIT 2018 24 895 M
Net income 2018 16 036 M
Debt 2018 12 563 M
Yield 2018 2,83%
P/E ratio 2018 18,33
P/E ratio 2019 16,48
EV / Sales 2018 4,37x
EV / Sales 2019 4,11x
Capitalization 343 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 143 $
Spread / Average Target 13%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-8.53%342 779
PFIZER3.98%220 295
NOVARTIS-1.75%206 001
ROCHE HOLDING LTD.-5.90%203 399
MERCK AND COMPANY11.09%169 328
AMGEN10.27%127 577